Two important contributors of early protection are speed of replication and onset of immunity, according to Alberto Giner, ...

CanSinoBIO’s vaccine is a recombinant viral vector vaccine, a class of vaccines that use a modified version of a different virus to deliver instructions to cells that trigger an immune response.

A variety of vaccine approaches, however, have been investigated using both inactivated virus and recombinant DNA technology. These approaches will be further discussed later in this review.

The Ad5-EBOV vaccine developed in China relies on the recombinant replication-defective human adenovirus type-5 vector to induce immune responses and provide protection against the Ebola virus.

Scientists have pioneered an influenza virus vector-based nasal spray vaccine platform and developed a nasal spray H5N1 avian influenza vaccine. During the early COVID-19 pandemic, this platform ...

Oncolytic adenovirus was engineered for the forced ectopic delivery of peptide-MHC ligand of T cell receptors (TCRs) to ...

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral ...

Triplex is a universal recombinant Modified Vaccinia Ankara viral vector vaccine. "Fortress doses first subject in Phase II ...

Cell- or recombinant-based influenza vaccines will include an A/Wisconsin/67/2022 (H1N1)pdm09-like virus; an A/District of Columbia/27/2023 (H3N2)-like virus; and a B/Austria/1359417/2021 (B ...

The participants were divided into a placebo group and five active groups that received different doses of the two vaccine ... vector components, namely the ChAdOx vector and the modified vaccinia ...

The combination of synchronous experimental process development and digital twin core model development is among the first of its kind.

The recombinant zoster vaccine (RZV) Shingrix demonstrated effectiveness in preventing herpes zoster (HZ) and postherpetic neuralgia among adults aged 50 years or older with rheumatoid arthritis (RA).